Lumira joins Engage Therapeutics' $23 mln Series A round

Summit, New Jersey-based clinical-stage biopharmaceutical company Engage Therapeutics Inc has closed a US$23 million Series A financing. The round was led by TPG Biotech with participation from Adage Capital Management and Lumira Capital, a Canadian life sciences venture capital firm. As a result, Lumira Managing Director Gerry Brunk will join the company's board. Engage is developing a new rescue therapy for people who experience uncontrolled epileptic seizures. It will use the funds raised to back the Phase 2b clinical trial of its lead candidate, Staccato alprazolam, an acute epileptic treatment.

CanadaNorth AmericaBriefs